You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股收評:恆指上揚7%重回21000點上方 內房股暴動 科技股繼續上漲

3月17日,港股延續昨日大反彈行情,市場情緒得以回穩。恆指漲7.04%重回21000點上方,2天連續收復3大整數關口,恆生科技指數漲7.76%,2日漲幅超千點,收復4500點大關。

盤面上,大型科技股繼續反彈,百度漲超16%,京東漲15.85%,阿里巴巴、美團漲超12%,騰訊漲超6%;內房股與物管股表現最為亮眼,融創中國盤中暴漲超60%,新城發展、龍光集團、雅生活服務、融創服務均飆漲逾40%,富力地產、佳兆業集團等多數個股漲幅均超30%;醫藥股、濠賭股、重型機械股、餐飲股、家電股、大型金融股、汽車股、石油股、燃氣股等紛紛上揚,市場一片大好。另一方面,惟K12教育、包裝食品個別板塊走低,新東方、中國旺旺逆勢下跌。

具體來看

內房股集體飆升,融創中國漲近60%,新城發展、時代中國、龍光集團漲超42%,佳兆業集團、世茂集團、旭輝控股、合景泰富等漲超30%。

消息面上,國務院金融委表示,要及時研究和提出有力有效的防範化解風險應對方案,提出向新發展模式轉型的配套措施;銀保監會表示,鼓勵機構穩妥有序開展併購貸款,重點支持優質房企兼併收購困難房企優質項目;財政部表示,今年內不具備擴大房地產税改革試點城市的條件。

物管股跟隨飆升,雅生活服務漲超48%,融創服務漲近47%,碧桂園服務、世茂服務、寶龍商業漲超30%。

中資券商股集體走強,東方證券、中信證券、中金公司漲超7%,中信建投、中國銀河等漲超5%,廣發證券、招商證券、光大證券等集體走高

消息面上,自2022年4月起將股票類業務最低結算備付金繳納比例自18%調降至16%。

抗疫概念股延續強勢,君實生物、騰盛博藥、中國生物製藥、阿里健康漲超12%,復星醫藥漲超10%,歌禮制藥漲近10%,四環醫藥漲超7%,康希諾生物漲超6%。

博彩股漲幅靠前,新濠國際發展、澳博控股漲超13%,金沙中國、美高梅中國、永利澳門漲超11%,銀河娛樂漲超9%。

大摩最新發研報指,濠賭股自2019年12月以來按市值計已累挫62%,相信市場反映了賭牌續期及新冠疫情影響旅客的兩大因素,從長線投資角度視此為短暫性因素。該行表示,假設澳門特區政府能正常地落實延長賭牌,估計濠賭股可潛在回升20%至30%,料EBITDA於2023年下半年至2024年可錄正常化。

銀行股漲幅靠前,渤海銀行漲超18%,招商銀行漲超9%,渣打集團、郵儲銀行、農業銀行漲超5%,交通銀行、工商銀行等紛紛走強。

個股異動 

嗶哩嗶哩收漲15.97%,報208.40港元,總市值807.73億港元;公司將自願尋求在港交所雙重上市。雙重上市是指兩個資本市場均為第一上市地。嗶哩嗶哩在港交所現為二次上市。

復星醫藥收漲11.37%,報33.30港元,總市值853.45億港元;35家藥企獲允許免費生產輝瑞新冠口服藥,包括5家中國企業,分別是上海迪賽諾、華海藥業、普洛藥業、復星醫藥、九洲藥業。 

南向資金淨流入24.43億港元,其中港股通(滬)淨流入-17.14億港元,港股通(深)淨流入41.57億港元。

展望後市,大摩發研報指,國務院要求金融機構必須從大局出發支持經濟發展、要保持資本市場穩定及支持企業境外上市等,該行相信內地相關聲明影響正面。該行表示,恆指近日已大幅回升至該行最熊情境目標19500點之上,而回到該行基本預測的路徑,目前比以前更發展清晰,或可能會持續很長時間。該行維持對中國資本市場「與大市同步」看法,大摩表示,中國資本市場要持續升勢,認為投資者要從五方面觀察,第一是中國對目前應對新冠疫情的政策會否調整,要觀察社交躍離措施對經濟活動的影響;第二是全球地緣政治緊張的因素;第三是內地樓市需要回穩;第四是當局的政策及執行需更為協調;第五是要增加投資者對離岸IPO市場復甦的信心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account